Induction of drug metabolising enzymes. Pharmacokinetic and toxicological consequences in humans

Clinical Pharmacokinetics

Volumn 38, Issue 6, 2000, Pages 493-504

  Fuhr, Uwe ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANDROSTANE DERIVATIVE; AROMATIC HYDROCARBON RECEPTOR; DRUG METABOLIZING ENZYME; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENOBARBITAL; RIFAMPICIN;

DRUG BIOAVAILABILITY; DRUG INTERACTION; DRUG METABOLISM; ENZYME INDUCTION; HUMAN; LIGAND BINDING; LIVER CLEARANCE; LIVER TOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0034042711     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200038060-00003     Document Type: Review

References (64)

1. 1. Whitlock JP, Denison MS. Induction of cytochrome P450 enzymes that metabolize xenobiotics. In. Ortiz tic Montellano P, editor. Cytochrome P450: structure, mechanism, and biochemistry, 2nd ed. New York: Plenum Press, 1995: 367-90
2. 2. Dogra SC, Whitelaw ML, May BK. Transcriptional activation of cytochrome P450 genes by different classes of chemical inducers. Clin Exp Pharmacol Physiol 1998; 25: 1-9
3. 3. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotetn in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147-53
4. 4. Fromm MF, Busse D, Kroemer HK, et al. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampicin. Hepatology 1996; 24: 796-801
5. 5. Tantcheva-Poor I, Zaigler M, Rietbrock S, et al. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 1999; 9: 131-44
6. 6. Klotz U, Ammon E. Clinical and toxicological consequences of the inductive potential of ethanol. Eur J Clin Pharmacol 1998; 54: 7-12
7. 7. Breckenridge A, Orme M. Clinical implications of enzyme induction. Ann N Y Acad Sci 1971; 179: 421-31
8. 8. Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102: 1016-23
9. 9. Sueyoshi T, Kawamoto T, Zelko I, et al. The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 1999; 274: 6043-6
10. 10. Chang TK, Yu L, Maurel P, et al. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997; 57: 1946-54
11. 11. Moore LB, Parks DJ, Jones SA, et al. Orphan nuclear receptors CAR and PXR share xenobiotic and steroid ligands. J Biol Chem 2000. In press
12. 12. Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 1999 Sep 1;369(1): 11-23
13. 13. Safe S, Krishnan V. Cellular and molecular biology of aryl hydrocarbon (Ah) receptor-mediated gene expression. Arch Toxicol 1995; Suppl. 17: 99-115
14. 14. Hayes JD, Pulford DJ. The glutathione S-transferaiD supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445-600
15. 15. Bock KW, Gschaidmeier H, Heel H, et al. AH receptor-controlled transcriptional regulation and function of rat and human UDP-glucuronosyltransferase isoforms. Adv Enzyme Regul 1998; 38: 207-22
16. 16. Shet MS, McPhaul M, Fisher CW, et al. Metabolism of the antiandrogenic drug (flutamide) by human CYP1A2. Drug Metab Dispos 1997; 25: 1298-303
17. 17. Schein JR. Cigarette smoking and clinically significant drug interactions. Ann Pharmacother 1995; 29: 1139-48
18. 18. Otero MJ, Buelga DS, Vazquez MA, et al. Application of population pharmacokinetics to the optimization of theophylline therapy. J Clin Pharm Ther 1996; 21: 113-25
19. 19. Perry PJ, Bever KA, Arndt S, et al. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 1998; 44: 733-8
20. 20. Fuhr U, Harder S, Lopez-Rojas P, et al. Increase of verapamil concentrations in steady state by coadministration of grapefruit juice [abstract]. Naunyn-Schmiedebergs Arch Pharmacol 1994; 349 Suppl.: R134
21. 21. Fontana RJ, Lown KS, Paine MF, et al. Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology 1999; 117: 89-98
22. 22. Probst-Hensch NM, Tannenbaum SR, Chan KK, et al. Absence of the glutathione S-transferase M1 gene increases cytochrome P4501A2 activity among frequent consumers of cruciferous vegetables in a Caucasian population. Cancer Epidemiol Biomarkers Prev 1998; 7: 635-8
23. 23. Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 1992; 13: 1561-8
24. 24. Jorritsma U, Schrader E, Klaunick G, et al. Monitoring of cytochrome P-450 IA activity by determination of the urinary pattern of caffeine metabolites in Wistar and hyperbilirubinemic Gunn rats. Toxicology 2000; 144: 229-36
25. 25. Diaz D, Fabre I, Daujat M, et al. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 1990; 99: 737-47
26. 26. Rost KL, Brosicke H, Heinemeyer G, et al. Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology 1994; 20: 1204-12
27. 27. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29: 413-580
28. 28. Anttila S, Vainio H, Hietanen E, et al. Immunohistochemical detection of pulmonary cytochrome P4501A and metabolic activities associated with P450IA1 and P450IA2 isozymes in lung cancer patients. Environ Health Perspect 1992; 98: 179-82
29. 29. Lang NP, Butler MA, Massengill J, et al. Rapid metabolic phenotypes for acetyltransferase and cytochrome P450IA2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Prev 1994; 3: 675-82
30. 30. Lee SW, Jang IJ, Shin SG, et al. CYP1A2 activity as a risk factor for bladder cancer. J Korean Med Sci 1994; 9: 482-9
31. 31. Rannug A, Alexandrie AK, Persson I, et al. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance. J Occup Environ Med 1995; 37: 25-36
32. 32. Gonzalez FJ, Ueno T, Umeno M, et al. Microsomal ethanol oxidizing system: transcriptional and posttranscriptional regulation of cytochrome P450, CYP2EI. Alcohol Alcohol 1991; Suppl. 1: 97-101
33. 33. Chien JY, Thummel KE, Slattery JT. Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab Dispos 1997; 25: 1165-75
34. 34. Zhukov A, Ingelman-Sundberg M. Relationship between cytochrome P450 catalytic cycling and stability: fast degradation of ethanol-inducible cytochrome P450 2EI (CYP2EI) in hepatoma cells is abolished by inactivation of its electron donor NADPH-cytochrome P450 reductase. Biochem J 1999; 340: 453-8
35. 35. Kharasch ED, Hankins D, Mautz D, et al. Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 1996; 347: 1367-71
36. 36. Raucy JL, Lasker JM, Lieber CS, et al. Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys 1989; 271: 270-83
37. 37. Lucas D, Farez C, Bardou LG, et al. Cytochrome P450 2EI activity in diabetic and obese patients as assessed by chlorzozaxone hydroxylation. Fundam Clin Pharmacol 1998; 12: 553-8
38. 38. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-93
39. 39. Demetri GD, Fletcher CD, Mueller E, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 1999; 96: 3951-6
40. 40. Winocour PH, Durrington PN, Bhatnagar D, et al. Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type I diabetes mellitus. Diabet Med 1990; 7: 736-43
41. 41. Durrington PN, Mackness MI, Bhatnagar D, et al. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. Atherosclerosis 1998; 138: 217-25
42. 42. Conney AH, Jacobson M, Schneidman K, et al. Induction of liver microsomal cortisol 6beta-hydroxylase by diphenylhydantoin or phenobarbital: an explanation for the increased excretion of 6-hydroxycortisol in humans treated with these drugs. Life Sci 1965; 4: 1091-8
43. 43. Remmer H, Estabrook RW, Schenkman J, et al. Reaction of drugs with microsomal liver hydroxylase: its influence on drug action. Naunyn Schmiedebergs Arch Exp Pathol Pharmacol 1968; 259: 98-116
44. 44. Frueh FW, Zanger UM, Meyer UA. Extent and character of phenobarbital-mediated changes in gene expression in the liver. Mol Pharmacol 1997 Mar; 51 (3): 363-9
45. 45. Meyer UA, Hoffmann K. Phenobarbital-mediated changes in gene expression in the liver. Drug Metab Rev 1999; 31: 365-73
46. 46. Forman BM, Tzameli I, Choi HS, et al. Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature 1998; 395: 612-5
47. 47. Schellens JH, van der Wart JH, Brugman M, et al. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a 'cocktail' study design. J Pharmacol Exp Ther 1989; 249: 638-45
48. 48. Sutherland L, Ebner T, Burchell B. The expression of UDP-glucuronosyltransferases of the UGTI family in human liver and kidney and in response to drugs. Biochem Pharmacol 1993; 45: 295-301
49. 49. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998; 32: 554-63
50. 50. Patsalos PN, Duncan JS. Antiepileptic drugs: a review of clinically significant drug interactions. Drug Saf 1993; 9: 156-84
51. 51. Pisani F, Fazio A, Artesi C, et al. An epidemiological study of the clinical impact of pharmacokinetic anticonvulsant drug interactions based on serum drug level analysis. Ital J Neurol Sci 1987; 8: 135-41
52. 52. Yukawa E, Aoyama T. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data. J Clin Pharmacol 1996; 36: 752-9
53. 53. Liu H, Delgado MR. Interactions of phenobarbital and phenytoin with carbamazepine and its metabolites' concentrations, concentration ratios, and level/dose ratios in epileptic children. Epilepsia 1995; 36: 249-54
54. 54. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin: part I. Clin Pharmacokinet 1990; 18: 37-60
55. 55. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin: part II. Clin Pharmacokinet 1990; 18: 131-50
56. 56. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. Clin Pharmacokinet 1996; 31: 198-214
57. 57. Rutledge DR, Pieper JA, Mirvis DM. Effects of chronic phenobarbital on verapamil disposition in humans. J Pharmacol Exp Ther 1988; 246: 7-13
58. 58. Rao-Schymanski RA, Fuhr U. Pharmacokinetic interactions of antineoplastic agents. Int J Clin Pharmacol Ther 1997; 35: 84-7
59. 59. Busse D, Busch FW, Schweizer E, et al. Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism. Cancer Chemother Pharmacol 1999; 43: 263-8
60. 60. Maezawa S, Ohira S, Sakuma M, et al. Effects of inducer of liver drug-metabolizing enzyme on blood level of active metabolites of cyclophosphamide in rats and in cancer patients. Tohoku J Exp Med 1981; 134: 45-53
61. 61. Whysner J, Ross PM, Williams GM. Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol Ther 1996; 71: 153-91
62. 62. Watanabe M, Tateishi T, Asoh M, et al. Effects of glucocorticoids on pharmacokinetics and pharmacodynamics of midazolam in rats. Life Sci 1998; 63: 1685-92
63. 63. LeBel M, Masson E, Guilbert E, et al. Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone. J Clin Pharmacol 1998; 38: 1042-50
64. 64. Fuhr U. Drug interactions with grapefruit juice: extent, probable mechanism and clinical relevance. Drug Saf 1998; 18: 251-72